{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:59:52Z","timestamp":1788188392498,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":241,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IDCases"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.idcr.2021.e01263","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T02:23:12Z","timestamp":1630462992000},"page":"e01263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Cerebral aspergillosis and facial acneiform lesions following initiation of ibrutinib in a patient with chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"26","author":[{"given":"Helbies","family":"Bedier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Frenette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Routy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idcr.2021.e01263_bib1","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.idcr.2021.e01263_bib2","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idcr.2021.e01263_bib3","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","article-title":"Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study","volume":"131","author":"Ahn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.idcr.2021.e01263_bib4","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1158\/1078-0432.CCR-16-1948","article-title":"Long-term follow-up of treatment with ibrutinib and rituximab in patients with high-risk chronic lymphocytic leukemia","volume":"23","author":"Jain","year":"2017","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"10.1016\/j.idcr.2021.e01263_bib5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2017-08-764712","article-title":"How I treat CLL patients with ibrutinib","volume":"131","author":"Brown","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.idcr.2021.e01263_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.idcr.2021.e01263_bib7","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.idcr.2021.e01263_bib8","first-page":"1593","article-title":"Ibrutinib for chronic lymphocytic leukemia","volume":"374","author":"Ruchlemer","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.idcr.2021.e01263_bib9","first-page":"27","article-title":"Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia","volume":"21","author":"Arthurs","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.idcr.2021.e01263_bib10","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1080\/10428194.2017.1320710","article-title":"Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis","volume":"58","author":"Baron","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.idcr.2021.e01263_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mmcr.2019.12.007","article-title":"A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy","volume":"27","author":"Eichenberger","year":"2019","journal-title":"Med Mycol Case Rep"},{"key":"10.1016\/j.idcr.2021.e01263_bib12","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.medmal.2018.01.003","article-title":"Cerebral aspergillosis: an emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia?","volume":"48","author":"Gaye","year":"2018","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.idcr.2021.e01263_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mmcr.2019.02.005","article-title":"Cranial aspergillosis in a patient receiving ibrutinib for chronic lymphocytic leukemia","volume":"24","author":"Beresford","year":"2019","journal-title":"Med Mycol Case Rep"},{"key":"10.1016\/j.idcr.2021.e01263_bib14","doi-asserted-by":"crossref","first-page":"240","DOI":"10.15252\/emmm.201404556","article-title":"Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus","volume":"7","author":"Herbst","year":"2015","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.idcr.2021.e01263_bib15","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-12-823393","article-title":"Ibrutinib blocks Btk-dependent NF-\u0138B and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis","volume":"132","author":"Bercusson","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.idcr.2021.e01263_bib16","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3324\/haematol.2019.219220","article-title":"Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus","volume":"105","author":"Blez","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.idcr.2021.e01263_bib17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2141.2000.02014.x","article-title":"Towards a targeted, risk-based, antifungal strategy in neutropenic patients","volume":"110","author":"Prentice","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.idcr.2021.e01263_bib18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s12550-018-0320-7","article-title":"Gliotoxin penetrates and impairs the integrity of the human blood-brain barrier in vitro","volume":"34","author":"Patel","year":"2018","journal-title":"Mycotoxin Res"},{"key":"10.1016\/j.idcr.2021.e01263_bib19","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/myc.13001","article-title":"Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: an observational study","volume":"62","author":"Ruchlemer","year":"2019","journal-title":"Mycoses"},{"key":"10.1016\/j.idcr.2021.e01263_bib20","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.clml.2017.07.005","article-title":"Cutaneous adverse events of targeted therapies for hematolymphoid malignancies","volume":"17","author":"Ransohoff","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["IDCases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250921002195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214250921002195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:04:02Z","timestamp":1761998642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214250921002195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":20,"alternative-id":["S2214250921002195"],"URL":"https:\/\/doi.org\/10.1016\/j.idcr.2021.e01263","relation":{},"ISSN":["2214-2509"],"issn-type":[{"value":"2214-2509","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cerebral aspergillosis and facial acneiform lesions following initiation of ibrutinib in a patient with chronic lymphocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"IDCases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idcr.2021.e01263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e01263"}}